Graft survival and long-term renal function after sequential conventional cyclosporin a therapy in cadaver kidney transplantation — a prospective randomized trial

1987 ◽  
Vol 65 (18) ◽  
pp. 879-884 ◽  
Author(s):  
R. Grundmann ◽  
U. Hesse ◽  
P. Wienand ◽  
C. Baldamus ◽  
W. Arns
2009 ◽  
Vol 41 (2) ◽  
pp. 648-650 ◽  
Author(s):  
I. Helal ◽  
E. Abderrahim ◽  
F. Ben Hamida ◽  
M. Ounissi ◽  
S. Essine ◽  
...  

2016 ◽  
Vol 29 (5) ◽  
pp. 619-626 ◽  
Author(s):  
Susan S. Wan ◽  
Marcelo Cantarovich ◽  
Istvan Mucsi ◽  
Dana Baran ◽  
Steven Paraskevas ◽  
...  

2014 ◽  
Author(s):  
Enrico Papini ◽  
Teresa Rago ◽  
Giovanni Gambelunghe ◽  
Roberto Valcavi ◽  
Giancarlo Bizzarri ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kyeong Deok Kim ◽  
Kyo Won Lee ◽  
Sang Jin Kim ◽  
Okjoo Lee ◽  
Manuel Lim ◽  
...  

AbstractThe use of kidneys from donation after brain death (DBD) donors with acute kidney injury (AKI) is a strategy to expand the donor pool. The aim of this study was to evaluate how kidney transplantation (KT) from a donor with AKI affects long-term graft survival in various situations. All patients who underwent KT from DBD donors between June 2003 and April 2016 were retrospectively reviewed. The KDIGO (Kidney Disease: Improving Global Outcomes) criteria were used to classify donor AKI. The cohort included 376 donors (no AKI group, n = 117 [31.1%]; AKI group n = 259 [68.9%]). Death-censored graft survival was similar according to the presence of AKI, AKI severity, and the AKI trend (p = 0.929, p = 0.077, and p = 0.658, respectively). Patients whose donors had AKI who received using low dose (1.5 mg/kg for three days) rabbit anti-thymocyte globulin (r-ATG) as the induction agent had significantly superior death-censored graft survival compared with patients in that group who received basiliximab (p = 0.039). AKI in DBD donors did not affect long-term death-censored graft survival. Low-dose r-ATG may be considered as an induction immunosuppression in recipients receiving kidneys with AKI because it showed better graft survival than basiliximab.


2008 ◽  
Vol 86 (Supplement) ◽  
pp. 582
Author(s):  
S Cristino ◽  
M P. Scolari ◽  
G La Manna ◽  
A Faenza ◽  
G Mosconi ◽  
...  

1996 ◽  
Vol 83 (8) ◽  
pp. 1082-1085 ◽  
Author(s):  
M. L. Nicholson ◽  
T. A. McCulloch ◽  
S. J. Harper ◽  
T. J. Wheatley ◽  
C. M. Edwards ◽  
...  

The Lancet ◽  
1981 ◽  
Vol 317 (8231) ◽  
pp. 1218-1219 ◽  
Author(s):  
D.V. Hamilton ◽  
R.Y. Calne ◽  
D.B. Evans ◽  
R.G. Henderson ◽  
S. Thiru ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document